Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.27 USD | -0.47% | -2.88% | -11.34% |
05-10 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
05-01 | RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept | MT |
- Stock Market
- Equities
- EXEL Stock
- Charts Exelixis, Inc.
- Static Chart